A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Phase 2 Unknown 36 enrolled Hebei Medical University

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the efficacy and safety of intraperitoneal and intravenous paclitaxel plus apatinib and S-1 in the conversion therapy of gastric cancer with positive exfoliative cancer cells

Timeline

Start: 2018-10-30
Primary completion: 2019-10-30
Completion: 2020-10-30

Publications

Ding P, Guo H, Ma W, Wu J, Wu H, Li T, Gu R, Zhang L, Meng N, Li X, Guo Z, Meng L, Zhao Q. Transcriptomics-driven non-invasive liquid biopsy for diagnosing peritoneal lavage cytology-positive gastric cancer. NPJ Precis Oncol. 2026 Jul 15. doi: 10.1038/s41698-026-01531-w. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paclitaxel	Small molecule	20 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	50 mg/m2	Intravenous
Subject	Rivoceranib	Small molecule	500 mg	Oral
Subject	S-1	Small molecule	40 mg	—
Subject	S-1	Small molecule	50 mg	—
Subject	S-1	Small molecule	60 mg	—

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Summary

Timeline

Publications

Drugs

Indications